Galectin Therapeutics Inc.

GALT · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$47,047-$41,066-$38,776-$30,527
Dep. & Amort.$37$33$32$41
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,447$2,261$2,867$2,076
Change in WC$2,284$4,678$4,968$3,751
Other Non-Cash$512$1,129-$147$351
Operating Cash Flow-$41,767-$32,965-$31,056-$24,308
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$30,000$30,000$10,000$30,000
Stock Issued$1,227$0$0$6,814
Stock Repurch.$0$0$0$0
Dividends Paid-$91$0$0-$171
Other Fin. Act.$91$10,033$0$171
Financing Cash Flow$31,227$40,033$10,000$36,814
Forex Effect$0$0$0$0
Net Chg. in Cash-$10,540$7,068-$21,056$12,506
Supplemental Information
Beg. Cash$25,660$18,592$39,648$27,142
End Cash$15,120$25,660$18,592$39,648
Free Cash Flow-$41,767-$32,965-$31,056-$24,308